Skip to NavigationSkip to content

Sanofi’s head of strategy and business development to retire amid company review

Published on 25/11/19 at 03:41pm

One of Sanofi’s most senior strategy bosses is set to retire at the end of the month. Muzammil Mansuri, Executive Vice President of Strategy and Business Development, leaves the company during a strategic review.

Mansuri started out as a research scientist at Shell before moving to Bristol-Meyers. His last role before joining Sanofi in 2016 was the Senior VP of R&D Strategy and Corporate Development at Gilead Sciences.

A spokesperson told Endpoints News that Mansuri had played a key role in Sanofi’s strategic moves over the last four years, overseeing acquisitions and ‘’structuring partnerships and alliances that contributed to the deployment of our strategy and growth’’.  Sanofi said that his retirement was planned.

It is the first management shakeup under new CEO Paul Hudson, who took over on 1 September. Under his leadership the company is carrying out a strategic review due to setbacks experienced under his predecessor. He inherited a company with an R&D department that lags behind the competition, a diabetes arm that is in decline and a slipping stock price. Hudson is expected to unveil the company’s plans for the future at an investor day on 10 December in Cambridge Massachusetts.

Conor Kavanagh

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches